Business
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat population was 96.0% at 3 months and 89.5% at 6 months - Efficacy was comparable across concurrent and sequential treatment arms and across both BCG-exposed and BCG-Unresponsive populations DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced positi
About this update from Cg Oncology, Inc.
[{"type":"image","alt":"CG Oncology Inc.","displaySize":"","headline":null,"caption":"CG Oncology Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":51,"url":"https://media.zenfs.com/en/globenewswire.com/e6d84dc2dcd899e87f2706074c7ed4f8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yn9PcvAQZE97v9_BbPMqQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcx/https://media.zenfs.com/en/globenewswire.com/e6d84dc2dcd899e87f2706074c7ed4f8","width":300,"height":51},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/yn9PcvAQZE97v9_BbPMqQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcx/https://media.zenfs.com/en/globenewswire.com/e6d84dc2dcd899e87f2706074c7ed4f8","width":300,"height":51}},"lazy":false},{"type":"text","content":"- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively","length":160,"tagName":"p"},{"type":"text","content":"- High-Grade - EFS in the overall intention-to-treat population was 96.0% at 3 months and 89.5% at 6 months","length":107,"tagName":"p"},{"type":"text","content":"- Efficacy was comparable across concurrent and sequential treatment arms and across both BCG-exposed and BCG-Unresponsive populations","length":134,"tagName":"p"},{"type":"text","content":"DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced positive first results from CORE‑008 Cohort CX, a Phase 2 study evaluating intravesical cretostimogene grenadenorepvec in combination with gemcitabine sequential versus concurrent treatment schedules in patients with high‑risk (HR) non‑muscle invasive bladder cancer (NMIBC). This trial includes HR NMIBC patients who are either BCG‑exposed or BCG‑unresponsive. The data, which demonstrate encouraging high-grade event-free survival (HG-EFS), high complete response (CR) rates and a well-tolerated safety profile, will be presented tomorrow at the Society of Urologic Oncology (SUO) Session at the 2026 American Urological Association (AUA) Annual Meeting in Washington, D.C.","length":765,"tagName":"p"},{"type":"text","content":"“Cohort CX was designed to assess whether combining cretostimogene with gemcitabine can further extend the strong clinical profile we have established with cretostimogene monotherapy,” said Vijay Kasturi, Chief Medical Officer of CG Oncology. “As the...